Cipla Falls Over 3% as US Slaps Import Alert on Partner Facility

Mumbai, April 24:Shares of Cipla fell as much as over three percent in Friday’s trade after the US Food and Drug Administration (USFDA) issued an import alert on a key partner facility, sparking concerns over supply disruptions in its critical US business.

The stock pared losses as the trading session progressed but the development casts a shadow on one of Cipla’s important growth drivers—its Lanreotide injection used in the treatment of hormonal disorders and certain cancers.

Import Alert

At the time of writing, the stock was down 1.4 percent at Rs 1,287.

The USFDA has placed an import alert on the Greece-based manufacturing facility of Cipla’s partner, Pharmathen, which produces the drug for the company’s US market. Animportalertimplies the regulator can detain shipments without physical examination, unless compliance issues are resolved, raising immediate concerns over supplies to the US. 

The move is significant because Cipla does not manufacture the drug in-house but relies on its partner for supply, making it particularly vulnerable to regulatory action at the third-party facility. The alert is expected to disrupt supplies of Lanreotide, which had been projected as a meaningful contributor to the company’s US revenues in the coming years. 

Long Haul

Analysts had estimated that the drug could generate around $50–60 million in revenue in FY27 and scale up to about $100 million in FY28. Those expectations are now under review, with the timeline for resolution of the regulatory issue remaining uncertain. Import alerts can often take months—or longer—to be lifted, depending on the extent of remediation required. 

The development also compounds existing concerns around Cipla’s US business, which contributes a significant portion of its overall revenue. The company has already been dealing with supply constraints in Lanreotide following earlier regulatory observations at the partner facility, making the latest action a further setback. 

Recent Nods

While Cipla recently secured approvals for other products in the US market, including respiratory therapies, the negative impact of the import alert appears to outweigh these positives in the near term. Market participants noted that the loss of a key revenue stream could offset gains from new launches, at least in the interim.

From a broader perspective, the episode highlights the risks associated with reliance on third-party manufacturing in highly regulated markets like the United States. Regulatory scrutiny remains intense, and even indirect exposure—through partners—can have a material impact on earnings visibility and investor sentiment.

For now, all eyes will be on how quickly the partner facility can address the USFDA’s concerns and restore compliance. Until then, Cipla’s stock may remain under pressure, with uncertainty around US revenues likely to keep investors cautious.

Source: 

• https://www.nseindia.com/get-quote/equity/CIPLA/Cipla-Limited
• NSE